A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

Condition(s) studied

Investigational drug(s) / intervention(s)

Divarasib: Divarasib will be administered orally as per the schedule specified in the respective arm.

Pembrolizumab: Pembrolizumab will be administered as either a 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) or 395 mg subcutaneous (SC) injection Q3W, for up to 13 cycles (1 cycle = 21 days).

Nivolumab: Nivolumab will be administered as either a 480 mg IV infusion, every 4 weeks (Q4W) or 1200 mg SC injection Q4W, for up to 13 cycles (1 cycle = 28 days).

Study summary

The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) status, who have not achieved pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy.

Eligibility

Primary outcome measure(s)

• Disease-free Survival (DFS), as Determined by the Investigator — From randomization to disease recurrence or death from any cause (Up to approximately 5 years)

Trial sites (46)

+ 6 more sites — see the full list on the official registry below.

On this site

More Hoffmann-La Roche trials in Japan

Other trials for the same condition